Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492304 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
A Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 7
- Study locations
NCT06492304 is a Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 290 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (152% higher). The trial reports 7 study locations across 6 states.
The verdict
NCT06492304, a Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Conditions Studied
Interventions
- BIOLOGICAL CTX131
Study Locations (7)
New York
- Research Site 4 - New York
- Research Site 2 - The Bronx
Arizona
- Research Site 6 - Phoenix
California
- Research Site 5 - Stanford
Massachusetts
- Research Site 3 - Boston
Texas
- Research Site 1 - Houston
Victoria
- Research Site 7 - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06492304
The ClinicalTrials.gov registry entry for NCT06492304 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (152% higher). The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CTX131 is the first listed.
NCT06492304 reports 7 study locations spanning 6 distinct geographic areas - top geographies include New York, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06492304 about?
NCT06492304 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies". This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
What is the current status of trial NCT06492304?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2024-08-13. Estimated completion is 2030-11.
What conditions does trial NCT06492304 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, B-cell Lymphoma, T-Cell Lymphoma.
What interventions are being tested in trial NCT06492304?
The interventions under investigation include: CTX131 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06492304?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492304 being conducted?
This trial has 7 study locations across Arizona, California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.